CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 300 · Search date 2026-07-11 · Methodology v0.6

Amla,
does it really help with Improvement in female pattern hair loss and hair growth?

30-Second Summary
C
Evidence Grade C · 44 · Safety acceptable
Only the hair-cycle outcome was positive in female pattern hair loss, while direct hair count and thickness were negative
What the
research shows
In a single RCT with 60 randomized and 52 completing, only the anagen-to-telogen ratio was positive at p=0.002. Direct hair count (p=0.382) and thickness (p=0.244) were negative, and baseline age was imbalanced at 33.1 years in the amla group versus 41.8 years with placebo, making the result dependent on adjustment. The amla, honey, and rosewater syrup used honey- and rosewater-matched placebo, allowing attribution to amla, but no independent replication exists. Female pattern hair loss is low C with 44 points.
What the
ads claim
Advertisements use phrases such as 'strengthens roots,' 'prevents hair loss,' 'hair growth,' and 'DHT management.' Direct human data consist of one 12-week trial of a specific syrup in female androgenetic alopecia.
*

Useful facts when choosing a product

  • The trial used 10 mL of amla syrup three times daily, totaling 30 mL/day.
  • The anagen-to-telogen ratio was positive, but direct hair count and thickness were negative.
  • The syrup contained amla, honey, and rosewater; placebo matched honey and rosewater.
  • One mild constipation case and no notable adverse effects were reported over 12 weeks.
Gap Measurement · Verdict 300 · C 44
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Akhbari 2024 assigned 60 women with female androgenetic alopecia to amla, honey, and rosewater syrup or a honey- and rosewater-matched placebo, and 52 completed. After 12 weeks, the anagen-to-telogen ratio was positive at p=0.002, but direct hair count was negative at p=0.382 and thickness at p=0.244. Baseline age differed at 33.1 years in the amla group versus 41.8 years with placebo, requiring adjusted analysis, and there is no independent replication.

02

Why this is classified as C (44)

The positive anagen-to-telogen ratio supports C for the hair-cycle subclaim in female pattern hair loss, while negative direct hair count and thickness support D for general growth. Fifty-two completers, baseline age imbalance requiring adjustment, one specific syrup, and no independent replication yield low C with 44 points. Other alopecia types and general hair growth lack evidence.

Counterpoint. A hair-cycle signal remains for a specific oral amla syrup in female pattern hair loss. Honey and rosewater matching permits attribution to amla, but the finding does not extend to direct count or thickness, other alopecia types, formulations, or long-term outcomes.

Rejudgment record. Reassessment (cross-check reflected) — In one RCT with 60 randomized and 52 completing, only the anagen-to-telogen ratio was positive, while count and thickness were negative; baseline age imbalance required adjustment and independent replication is absent

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Female pattern hair loss (hair cycle)CA single RCT found a positive anagen-to-telogen ratio at p=0.002
General hair count and thicknessDNegative in the single RCT

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Akhbari M et al. 2024Triple-blind randomized placebo-controlled RCT52UnknownTrichoScan anagen-to-telogen ratio, hair count and thickness, CGI-I, and PGI-IThe ratio was positive at p=0.002, while hair count at p=0.382 and thickness at p=0.244 were negative; baseline age was imbalanced at 33.1 versus 41.8 years.Key, single trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-07-11).

Akhbari M, Firooz A, Rahimi R, Shirzad M, Esmaealzadeh N, Shirbeigi L. The effect of an oral product containing Amla fruit (Phyllanthus emblica L.) on female androgenetic alopecia: A randomized controlled trial. J Ethnopharmacol. 2024;318(Pt A):116958. PMID: 37487962. DOI: 10.1016/j.jep.2023.116958.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Amla (Phyllanthus emblica) x improvement in female pattern hair loss and hair growth Evidence Grade C card
[Chamgap] Amla (Phyllanthus emblica) x improvement in female pattern hair loss and hair growth — Evidence Grade C·44. 1 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/skin-hair/amla-female-pattern-hair-loss-growth/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.